EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer

Yue Zhang, Shuyi Chen, Jie Ma, Xinchen Sun, Xiaobin Zhou

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04309-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yue Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical Laboratory Center, Gaogang Branch, Taizhou School of Clinical Medicine, Nanjing Medical University, The Affiliated Taizhou People's …. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Microenvironment, Biomarkers, Tumor, B7-H1 Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Medical Research Project of Jiangsu Provincial Healthcare Commission, Taizhou Social Development Project, the NSFC Cultivation Project of Nanjing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed cell death ligand 1 (PD-L1) plays a pivotal role in breast cancer immune evasion, yet tissue-based detection suffers from invasiveness and spatial heterogeneity. This study investigated circulating soluble PD-L1 (sPD-L1) as a non-invasive alternative for tumor microenvironment (TME) assessment and breast cancer diagnosis. Serum sPD-L1 levels were evaluated in healthy and breast-affected populations, with correlations assessed against inflammatory markers and clinicopathological parameters. Diagnostic performance of sPD-L1 was compared to conventional biomarkers using receiver operating characteristic (ROC) curve analysis. Cellular-level interactions were investigated by quantifying sPD-L1 and interleukin-6 (IL-6) in culture supernatants. Circulating sPD-L1 expression was significantly elevated in breast cancer versus healthy controls and benign cases, with notably higher levels observed in advanced stages and distant-metastatic cases. Moderate correlations were observed between serum sPD-L1 and various inflammatory indicators. Specifically, ROC curve analysis identified an optimal diagnostic cut-off value of 1.144 ng/mL for sPD-L1, with its discriminative power outperforming conventional biomarkers such as CEA and CA15-3. In vitro, peripheral blood mononuclear cells (PBMCs) co-cultured with breast cancer cells showed enhanced sPD-L1 and IL-6 secretion versus normal epithelial cell co-cultures, with parallel sPD-L1/IL-6 elevation. This coordinated induction was clinically validated by a positive serum sPD-L1/IL-6 correlation. In conclusion, circulating sPD-L1 represents a promising non-invasive biomarker reflecting TME and disease progression, supporting its potential utility for breast cancer diagnostic discrimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTumor MicroenvironmentBiomarkers, TumorB7-H1 AntigenHumansFemaleMiddle AgedInterleukin-6ROC CurveAdultAgedLeukocytes, Mononuclear

Stichwörter der Autor:innen

BiomarkerBreast cancerCancer diagnosisTumor immunitysPD-L1

Substanzen

Biomarkers, TumorB7-H1 AntigenCD274 protein, humanInterleukin-6

Autor:innen und Institutionen

  • Clinical Medical Laboratory Center, Gaogang Branch, Taizhou School of Clinical Medicine, Nanjing Medical University, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, China. yue_zh…
  • Clinical Medical Laboratory Center, Gaogang Branch, Taizhou School of Clinical Medicine, Nanjing Medical University, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, China.
  • Clinical Laboratory Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
  • Clinical Medical Laboratory Center, Gaogang Branch, Taizhou School of Clinical Medicine, Nanjing Medical University, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, China. shoppi…

Förderung

  • The Medical Research Project of Jiangsu Provincial Healthcare Commission
  • Taizhou Social Development Project
  • the NSFC Cultivation Project of Nanjing Medical University
  • Taizhou 311 High-level Talent Cultivation Project

Zitieren

APA

Zhang, Y., Chen, S., Ma, J., Sun, X., & Zhou, X. (2026). Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04309-y

Vancouver

Zhang Y, Chen S, Ma J, Sun X, Zhou X. Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04309-y

BibTeX
@article{Zhang2026,
  author = {Zhang, Yue and Chen, Shuyi and Ma, Jie and Sun, Xinchen and Zhou, Xiaobin},
  title = {Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04309-y}
}
Kostenlos starten →